PL1874278T3 - Kompozycje zawierające mikronizowany tanaproget - Google Patents
Kompozycje zawierające mikronizowany tanaprogetInfo
- Publication number
- PL1874278T3 PL1874278T3 PL06824718T PL06824718T PL1874278T3 PL 1874278 T3 PL1874278 T3 PL 1874278T3 PL 06824718 T PL06824718 T PL 06824718T PL 06824718 T PL06824718 T PL 06824718T PL 1874278 T3 PL1874278 T3 PL 1874278T3
- Authority
- PL
- Poland
- Prior art keywords
- compositions
- containing micronized
- micronized tanaproget
- hormone
- benign
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- PYVFWTPEBMRKSR-UHFFFAOYSA-N tanaproget Chemical compound CN1C(C#N)=CC=C1C1=CC=C(NC(=S)OC2(C)C)C2=C1 PYVFWTPEBMRKSR-UHFFFAOYSA-N 0.000 title abstract 2
- 229950001471 tanaproget Drugs 0.000 title abstract 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 abstract 1
- 201000009030 Carcinoma Diseases 0.000 abstract 1
- 229920002785 Croscarmellose sodium Polymers 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 abstract 1
- 206010046798 Uterine leiomyoma Diseases 0.000 abstract 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 abstract 1
- 208000009956 adenocarcinoma Diseases 0.000 abstract 1
- 230000000740 bleeding effect Effects 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 abstract 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 abstract 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 abstract 1
- 229960001681 croscarmellose sodium Drugs 0.000 abstract 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 210000004696 endometrium Anatomy 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 235000012631 food intake Nutrition 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 238000002657 hormone replacement therapy Methods 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 201000010260 leiomyoma Diseases 0.000 abstract 1
- 235000019359 magnesium stearate Nutrition 0.000 abstract 1
- 229940057948 magnesium stearate Drugs 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 230000002632 myometrial effect Effects 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 210000001672 ovary Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001817 pituitary effect Effects 0.000 abstract 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 229940069328 povidone Drugs 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Hematology (AREA)
- Pregnancy & Childbirth (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67559905P | 2005-04-28 | 2005-04-28 | |
| EP06824718A EP1874278B1 (en) | 2005-04-28 | 2006-04-26 | Compositions containing micronized tanaproget |
| PCT/US2006/016025 WO2007030153A2 (en) | 2005-04-28 | 2006-04-26 | Compositions containing micronized tanaproget |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1874278T3 true PL1874278T3 (pl) | 2009-12-31 |
Family
ID=37836301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL06824718T PL1874278T3 (pl) | 2005-04-28 | 2006-04-26 | Kompozycje zawierające mikronizowany tanaproget |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8343965B2 (pl) |
| EP (1) | EP1874278B1 (pl) |
| JP (3) | JP5149161B2 (pl) |
| CN (1) | CN101166521A (pl) |
| AT (1) | ATE434434T1 (pl) |
| AU (1) | AU2006287925B2 (pl) |
| BR (1) | BRPI0610438A2 (pl) |
| CA (1) | CA2603817C (pl) |
| DE (1) | DE602006007453D1 (pl) |
| DK (1) | DK1874278T3 (pl) |
| ES (1) | ES2327783T3 (pl) |
| MX (1) | MX2007013468A (pl) |
| PL (1) | PL1874278T3 (pl) |
| WO (1) | WO2007030153A2 (pl) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602006013114D1 (de) | 2005-04-28 | 2010-05-06 | Wyeth Corp | Mikronisiertes tanaproget und zusammensetzungen damit |
| MX2007013469A (es) * | 2005-04-28 | 2008-01-22 | Wyeth Corp | Forma ii polimorfa de tanaproget. |
| WO2006116514A2 (en) * | 2005-04-28 | 2006-11-02 | Wyeth | Micronized tanaproget, compositions, and methods of preparing the same |
| CA2603817C (en) | 2005-04-28 | 2013-03-19 | Wyeth | Compositions containing micronized tanaproget prepared by wet granulation |
| WO2006135638A2 (en) | 2005-06-09 | 2006-12-21 | Wyeth | Tanaproget compositions containing ethinyl estradiol |
| EA201070715A1 (ru) * | 2007-12-20 | 2011-02-28 | Тева Вимен'С Хелс, Инк. | Режимы дозирования, фармацевтические композиции и упаковки для экстренной контрацепции |
| US8512745B2 (en) * | 2008-12-08 | 2013-08-20 | Laboratoire Hra Pharma | Ulipristal acetate tablets |
| US10071059B2 (en) | 2009-12-18 | 2018-09-11 | Frieslandcampina Nederland Holding B.V. | Co-processed tablet excipient composition its preparation and use |
| EP2545922A1 (en) * | 2011-07-12 | 2013-01-16 | PregLem S.A. | Treatment of excessive menstrual bleeding associated with uterine fibroids |
| CN117835971A (zh) | 2021-08-25 | 2024-04-05 | 巴斯夫欧洲公司 | 直接压片用辅料组合物 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK95093D0 (da) | 1993-08-20 | 1993-08-20 | Novo Nordisk As | Farmaceutisk formulering indeholdende et hormon |
| JP4958338B2 (ja) * | 1999-05-04 | 2012-06-20 | ワイス・エルエルシー | プロゲステロン受容体モジュレーターとしてのシクロチオカルバメート誘導体 |
| UA73119C2 (en) * | 2000-04-19 | 2005-06-15 | American Home Products Corpoir | Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors |
| US7056906B2 (en) * | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
| IL165397A0 (en) * | 2002-06-25 | 2006-01-15 | Wyeth Corp | Cyclothiocarbamative derivatives as pr modulators and use thereof for treatment of skin disorders |
| CN1662241A (zh) * | 2002-06-25 | 2005-08-31 | 惠氏公司 | 环硫代氨基甲酸酯衍生物在治疗与激素有关的病症中的用途 |
| AU2003285189B2 (en) * | 2002-11-14 | 2006-07-27 | Shear/Kershman Laboratories, Inc. | Oral testosterone delivery system with improved sustained release |
| US8404272B2 (en) * | 2003-06-26 | 2013-03-26 | Poly-Med, Inc. | Fiber-reinforced composite rings for intravaginal controlled drug delivery |
| AU2005237520B2 (en) * | 2004-04-27 | 2012-01-19 | Wyeth | Purification of progesterone receptor modulators |
| AU2005238520B2 (en) * | 2004-04-27 | 2011-09-08 | Wyeth | Cyanopyrrole containing cyclic carbamate and thiocarbamate biaryls and methods for preparing the same |
| AR049707A1 (es) | 2004-07-07 | 2006-08-30 | Wyeth Corp | Regimenes y kits de progestina ciclica |
| GT200500185A (es) * | 2004-08-09 | 2006-04-10 | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
| GT200500183A (es) * | 2004-08-09 | 2006-04-10 | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
| MX2007001812A (es) * | 2004-08-13 | 2007-03-26 | Wyeth Corp | Derivados de tanaproget, metabolitos, y usos de los mismos. |
| US7496489B2 (en) * | 2004-08-20 | 2009-02-24 | Wyeth | Design of progesterone receptor ligands |
| CN101184738B (zh) * | 2005-04-28 | 2012-05-23 | 惠氏公司 | 纯化型的tanaproget |
| CA2603817C (en) | 2005-04-28 | 2013-03-19 | Wyeth | Compositions containing micronized tanaproget prepared by wet granulation |
| WO2006116514A2 (en) | 2005-04-28 | 2006-11-02 | Wyeth | Micronized tanaproget, compositions, and methods of preparing the same |
| MX2007013469A (es) | 2005-04-28 | 2008-01-22 | Wyeth Corp | Forma ii polimorfa de tanaproget. |
| DE602006013114D1 (de) | 2005-04-28 | 2010-05-06 | Wyeth Corp | Mikronisiertes tanaproget und zusammensetzungen damit |
| WO2006135638A2 (en) | 2005-06-09 | 2006-12-21 | Wyeth | Tanaproget compositions containing ethinyl estradiol |
-
2006
- 2006-04-26 CA CA2603817A patent/CA2603817C/en not_active Expired - Fee Related
- 2006-04-26 CN CNA2006800142222A patent/CN101166521A/zh active Pending
- 2006-04-26 EP EP06824718A patent/EP1874278B1/en not_active Not-in-force
- 2006-04-26 JP JP2008509120A patent/JP5149161B2/ja not_active Expired - Fee Related
- 2006-04-26 US US11/412,014 patent/US8343965B2/en not_active Expired - Fee Related
- 2006-04-26 PL PL06824718T patent/PL1874278T3/pl unknown
- 2006-04-26 DK DK06824718T patent/DK1874278T3/da active
- 2006-04-26 BR BRPI0610438-0A patent/BRPI0610438A2/pt not_active IP Right Cessation
- 2006-04-26 ES ES06824718T patent/ES2327783T3/es active Active
- 2006-04-26 AT AT06824718T patent/ATE434434T1/de not_active IP Right Cessation
- 2006-04-26 MX MX2007013468A patent/MX2007013468A/es active IP Right Grant
- 2006-04-26 DE DE602006007453T patent/DE602006007453D1/de active Active
- 2006-04-26 WO PCT/US2006/016025 patent/WO2007030153A2/en not_active Ceased
- 2006-04-26 AU AU2006287925A patent/AU2006287925B2/en not_active Ceased
-
2012
- 2012-07-31 JP JP2012169806A patent/JP2012254999A/ja active Pending
- 2012-11-29 US US13/689,177 patent/US8791109B2/en not_active Expired - Fee Related
-
2014
- 2014-05-26 JP JP2014108568A patent/JP2014205683A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2603817C (en) | 2013-03-19 |
| ATE434434T1 (de) | 2009-07-15 |
| DK1874278T3 (da) | 2009-09-28 |
| CN101166521A (zh) | 2008-04-23 |
| JP2008539264A (ja) | 2008-11-13 |
| MX2007013468A (es) | 2008-01-21 |
| US20060247234A1 (en) | 2006-11-02 |
| EP1874278A2 (en) | 2008-01-09 |
| US20130142838A1 (en) | 2013-06-06 |
| CA2603817A1 (en) | 2007-03-15 |
| JP2014205683A (ja) | 2014-10-30 |
| AU2006287925A1 (en) | 2007-03-15 |
| AU2006287925B2 (en) | 2012-03-01 |
| US8343965B2 (en) | 2013-01-01 |
| ES2327783T3 (es) | 2009-11-03 |
| JP2012254999A (ja) | 2012-12-27 |
| WO2007030153A3 (en) | 2007-08-09 |
| DE602006007453D1 (de) | 2009-08-06 |
| US8791109B2 (en) | 2014-07-29 |
| EP1874278B1 (en) | 2009-06-24 |
| JP5149161B2 (ja) | 2013-02-20 |
| WO2007030153A2 (en) | 2007-03-15 |
| BRPI0610438A2 (pt) | 2012-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1110017T1 (el) | Μικρονισμενη ταναπρογετη και συνθεσεις που περιεχουν αυτην | |
| EP1896034B8 (en) | Micronized tanaproget compositions and methods of preparing the same | |
| TW200716621A (en) | Polymorph form II of tanaproget | |
| PL1874278T3 (pl) | Kompozycje zawierające mikronizowany tanaproget | |
| JP2005511491A5 (pl) | ||
| PH12012501129A1 (en) | Neutralizing prolactin receptor antibodies and their therapeutic use | |
| RU2007101304A (ru) | Модуляторы рецептора прогестерона, содержащие производные пиррол-оксиндола и применение | |
| TW200731969A (en) | Use of progesterone receptor modulators | |
| CL2012000166A1 (es) | Compuesto (11beta,17beta)-17-hidroxi-11-[4-(metilsulfonil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-ona; y su uso para el tratamiento y/o la prevencion de fibroides uterinos, endometriosis, sangrados menstruales severos, meningiomas, cancer de mama hormonodependiente y de trastornos asociados a la menopausia, entre otros. | |
| AU2003255820A8 (en) | Derivatives of 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazole as antagonists of the gonadotropin releasing hormone (gnrh) for use in the treatment of sex hormone related conditions, such as prostatic of uterine cancer | |
| AU2003288644A1 (en) | Mercapto-phenyl-naphthyl-methane derivatives and preparation thereof | |
| EA201491344A1 (ru) | Производные спироиндолина в качестве антагонистов рецептора гонадотропин-рилизинг гормона | |
| MX2009001698A (es) | Derivados de oxazolidona como moduladores pr. | |
| DE602005019905D1 (de) | -modulatoren | |
| UA83928C2 (ru) | Производное пропан-1,3-диона или его соль | |
| CN105796567A (zh) | 新利司他固体分散体及其药物制剂 | |
| ATE275973T1 (de) | Empfängnisverhütende zusammensetzungen die progestagen und progesteronantagonisten enthalten | |
| CY1109919T1 (el) | Παραγωγα της ινδολης που ειναι χρησιμα σα ρυθμιστες του υποδοχεα της προγεστερονης | |
| MX2009009515A (es) | Cianopirrol sulfonamidas utiles para la modulacion del receptor de progesterona. | |
| EA201000097A1 (ru) | 8-бета-замещенные эстратриены в качестве селективно активных эстрогенов | |
| JP2008517871A5 (pl) | ||
| EA200702524A1 (ru) | Нестероидные модуляторы рецептора прогестерона | |
| WO2008112498A3 (en) | Synthesis and characterization of polymorph form ii of 4-(2-(4,4-dimethyl-2-oxooxazolidin-3-yl)thiazol-4-yl)benzonitrile | |
| Cheng et al. | Apoptosis and Endometriosis | |
| JP2020114805A (ja) | エストロゲン受容体α阻害作用を有するエストロゲン受容体βパーシャルアゴニストを用いた、子宮内膜症、子宮腺筋症等の婦人科疾患の疼痛、及び／又は器質的病変の治療剤 |